Biblio Discovery — Demo Discovery Service

15 results for "Muhammad Shaalan Beg"

Showing 1–15 · 1.63 seconds · RSS

  1. Journal Article Full text

    Impact of Diabetes Mellitus on the Outcome of Pancreatic Cancer

    Muhammad Shaalan Beg; Alok Kumar Dwivedi; Syed Arif Ahmad et al.

    PLoS ONE, Vol. 9 No. 5 · 2014 · English · PLOS Scopus

    Introduction: Diabetes mellitus (DM) has the potential to impact the pathogenesis, treatment, and outcome of pancreatic cancer. This study evaluates the impact of DM on pancreatic cancer survival. Methods: We conducted a retrospective cohort study from the Veterans Affairs (VA) Central Cancer…

    Also available at: DOAJ

  2. Journal Article

    Characteristics and impact of the most-cited palliative oncology studies from 1995 to 2016

    Corbin Eule; Nizar Bhulani; Elizabeth Paulk et al.

    BMC Cancer, Vol. 18 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background Palliative care, as a relatively young field within medicine, has increasingly used original research to validate and standardize its practice. In particular, palliative care has been incorporated into oncology to better address end-of-life decisions and care. The goal of this…

  3. Journal Article

    Twitter Conversations About Pancreatic Cancer by Health Care Providers and the General Public: Thematic Analysis

    Udhayvir Singh Grewal; Arjun Gupta; Jamie Doggett et al.

    JMIR Cancer, Vol. 8 No. 1 · 2022 · English · DOAJ Scopus

    Background There is a growing interest in the pattern of consumption of health-related information on social media platforms. ObjectiveWe evaluated the content of discussions around pancreatic cancer on Twitter to identify subtopics of greatest interest to health care providers and the general…

  4. Journal Article

    Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers

    David Hsiehchen; Leslie Bucheit; Dong Yang et al.

    Nature Communications, Vol. 13 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Acquired resistance to systemic treatments is inevitable in most cancers, but the genetic basis for this in many cancer types has remained elusive due to constraints in obtaining tissue specimens longitudinally. In the management of gastrointestinal cancers, molecular profiling is…

  5. Journal Article

    A qualitative study to explore the acceptability and usefulness of personalized biofeedback to motivate physical activity in cancer survivors

    Grace E. Brannon; Madison Ray; Patrick Cho et al.

    Digital Health, Vol. 8 · 2022 · English · DOAJ Scopus

    Objective Many cancer survivors do not meet recommended levels of exercise, despite the benefits physical activity offers. This study aimed to understand experiences of insufficiently active overweight/obese breast or colorectal cancer survivors, in efforts to (1) examine regular physical activity…

  6. Journal Article

    Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma

    Davendra P. S. Sohal; Mai Chi Duong; Syed Ameen Ahmad et al.

    JAMA Oncology · 2021 · English · OpenAlex Scopus

    Importance: Clinical outcomes after curative treatment of resectable pancreatic ductal adenocarcinoma (PDA) remain suboptimal. To assess the potential of early control of systemic disease with multiagent perioperative chemotherapy, we conducted a prospective trial. Objective: To determine 2-year…

  7. Journal Article

    Surgical Outcome Results From SWOG S1505

    Syed Arif Ahmad; Mai Chi Duong; Davendra P. S. Sohal et al.

    Annals of Surgery · 2020 · English · OpenAlex Scopus

    OBJECTIVE: The optimal neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. METHODS: S1505 (NCT02562716) was a randomized phase II study of perioperative chemotherapy with mFOLFIRINOX (Arm 1) or gemcitabine/nab-paclitaxel…

  8. Journal Article

    Survival of cancer survivors with a new pancreatic cancer diagnosis

    Sandi L. Pruitt; Anna Tavakkoli; Hong Zhu et al.

    Cancer Medicine, Vol. 12 No. 1 · 2023 · English · DOAJ Scopus

    Abstract Background Persons newly diagnosed with pancreas cancer and who have survived a previous cancer are often excluded from clinical trials, despite limited evidence about their prognosis. We examined the association between previous cancer and overall survival. Methods This US…

  9. Journal Article Full text

    Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS

    Emil Lou; Joanne Xiu; Yasmine Baca et al.

    Cells, Vol. 10 No. 6 · 2021 · English · DOAJ Scopus

    The molecular heterogeneity of KRAS is well established, with a pool of variants comprising >75% of all known mutations; this pool includes mutations in classic codons 12, 13, and 61, as well as 146 and 117. In addition, there are rare variants that are more frequently encountered clinically due to…

  10. Journal Article Full text

    Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours

    David S. Hong; Yoon‐Koo Kang; Mitesh J. Borad et al.

    British Journal of Cancer · 2020 · English · OpenAlex Scopus

    BACKGROUND: In this first-in-human, Phase 1 study of a microRNA-based cancer therapy, the recommended Phase 2 dose (RP2D) of MRX34, a liposomal mimic of microRNA-34a (miR-34a), was determined and evaluated in patients with advanced solid tumours. METHODS: Adults with various solid tumours…

  11. Journal Article Full text

    Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Edward Dela Cruz Drilon; D. Ross Camidge; W. Marston Linehan et al.

    New England Journal of Medicine · 2024 · English · OpenAlex Scopus

    The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI…